{ "title": "Peptide Local Peptide Evidence and Status Index", "version": "2026-07-24", "canonicalLandingPage": "/data/peptide-evidence-index", "scope": "Published Peptide Local identity, FDA medicine, clinical pipeline, and qualified US research-market records.", "boundary": "A source-routing and identity dataset across three different evidence categories. Record count and linked-source count do not measure clinical strength, safety, efficacy, product quality, legal access, or suitability for use.", "methodology": "/methodology", "comparisonTool": "/compare/peptides", "clinicalTrialDataset": "/data/peptide-clinical-trials", "dataDictionary": { "record_id": "Stable Peptide Local identifier for the evidence record.", "name": "Published record name. Medicine rows include the exact brand and active ingredient.", "aliases": "Alternate names, former names, sponsor codes, application identifiers, or common search forms used for identity resolution.", "evidence_category": "One of medicine, pipeline, or market. Categories answer different questions and must not be merged into one safety or efficacy scale.", "family": "Editorial classification used for browsing related records; it is not a therapeutic recommendation.", "sponsor_company_or_board": "Sponsor for a pipeline program, label company for an approved medicine, or exact-size definition for a research-market board.", "current_status": "Current status statement carried by the canonical profile on the checked date.", "route_or_listing_detail": "Route and dosage-form context for medicine and pipeline records, or seller-listing category context for research-market boards.", "question_answered": "The bounded question this category of record is designed to answer.", "interpretation_boundary": "The main conclusion the row does not support.", "linked_evidence_records": "Count of sources or seller observations attached to the canonical profile. This is coverage, not an evidence-quality score.", "clinical_trial_records": "Count of ClinicalTrials.gov records matched to a pipeline identity by the current 13-program exact-intervention snapshot. Blank for evidence categories outside that snapshot, not zero.", "recruiting_clinical_trials": "Matched registry records whose overall status was Recruiting at the snapshot timestamp. Registry status does not establish individual eligibility or site access.", "posted_trial_results": "Matched registry records with a posted ClinicalTrials.gov results module. A blank or zero does not prove that no result exists elsewhere.", "clinical_trial_finder_path": "Peptide Local trial-finder route filtered to the matched pipeline program when available.", "clinical_trial_snapshot_version": "Version of the ClinicalTrials.gov snapshot used for identity linkage.", "clinical_trial_coverage_scope": "Explicit statement describing whether the row is covered by the current 13-program snapshot and how blanks must be interpreted.", "checked_date": "ISO date when the canonical record and its primary route were last reviewed.", "profile_path": "Canonical Peptide Local profile path for definitions, context, and additional citations.", "source_publisher": "Publisher responsible for the primary external record linked by the row.", "source_url": "Direct HTTPS route to the primary external record without affiliate parameters." }, "stats": { "records": 40, "aliases": 139, "evidenceReferences": 211, "categories": 3, "medicines": 7, "pipeline": 13, "market": 20, "sourcePublishers": 4, "trialLinkedProfiles": 13, "clinicalTrialSnapshotRecords": 268, "recruitingClinicalTrialRecords": 61, "postedClinicalTrialResults": 11, "clinicalTrialSnapshotVersion": "2026-07-24" }, "records": [ { "recordId": "market-aod-9604", "name": "AOD-9604", "aliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceCategory": "market", "evidenceCategoryLabel": "US research-market price board", "family": "Growth-signaling analogues", "sponsorCompanyOrBoard": "5 mg like-for-like comparison", "currentStatus": "3 of 4 rows in stock", "routeOrListingDetail": "Synthetic human growth hormone fragment research material", "questionAnswered": "What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access?", "interpretationBoundary": "Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.", "linkedEvidenceRecords": 5, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/products/aod-9604", "sourceLabel": "Read the FDA source", "sourcePublisher": "U.S. Food and Drug Administration", "sourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" }, { "recordId": "market-bpc-157", "name": "BPC-157", "aliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceCategory": "market", "evidenceCategoryLabel": "US research-market price board", "family": "Tissue and thymic peptides", "sponsorCompanyOrBoard": "10 mg like-for-like comparison", "currentStatus": "5 of 7 rows in stock", "routeOrListingDetail": "Synthetic pentadecapeptide research material", "questionAnswered": "What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access?", "interpretationBoundary": "Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.", "linkedEvidenceRecords": 8, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/products/bpc-157", "sourceLabel": "Read the FDA source", "sourcePublisher": "U.S. Food and Drug Administration", "sourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" }, { "recordId": "pipeline-cagrilintide", "name": "Cagrilintide", "aliases": [ "AM833", "NNC0174-0833" ], "evidenceCategory": "pipeline", "evidenceCategoryLabel": "Investigational clinical program", "family": "Obesity and metabolic pipeline", "sponsorCompanyOrBoard": "Novo Nordisk", "currentStatus": "Phase 3 monotherapy program", "routeOrListingDetail": "Long-acting amylin analogue · Once-weekly subcutaneous injection", "questionAnswered": "Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program?", "interpretationBoundary": "Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.", "linkedEvidenceRecords": 7, "clinicalTrialRecords": 52, "recruitingClinicalTrials": 10, "postedTrialResults": 2, "clinicalTrialFinderPath": "/clinical-trials?program=cagrilintide#trial-results", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Exact named-intervention match in the current 13-program ClinicalTrials.gov snapshot. Registry status, location, and posted results are separate fields and do not establish eligibility, access, approval, or benefit-risk.", "checkedDate": "2026-07-20", "profilePath": "/pipeline/cagrilintide", "sourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "sourcePublisher": "ClinicalTrials.gov", "sourceUrl": "https://clinicaltrials.gov/study/NCT05567796" }, { "recordId": "pipeline-cagrisema", "name": "CagriSema", "aliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceCategory": "pipeline", "evidenceCategoryLabel": "Investigational clinical program", "family": "Obesity and metabolic pipeline", "sponsorCompanyOrBoard": "Novo Nordisk", "currentStatus": "Phase 3 / US regulatory review", "routeOrListingDetail": "Amylin analogue + GLP-1 receptor agonist · Once-weekly subcutaneous injection", "questionAnswered": "Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program?", "interpretationBoundary": "Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.", "linkedEvidenceRecords": 8, "clinicalTrialRecords": 30, "recruitingClinicalTrials": 5, "postedTrialResults": 0, "clinicalTrialFinderPath": "/clinical-trials?program=cagrisema#trial-results", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Exact named-intervention match in the current 13-program ClinicalTrials.gov snapshot. Registry status, location, and posted results are separate fields and do not establish eligibility, access, approval, or benefit-risk.", "checkedDate": "2026-07-20", "profilePath": "/pipeline/cagrisema", "sourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "sourcePublisher": "ClinicalTrials.gov", "sourceUrl": "https://clinicaltrials.gov/study/NCT05567796" }, { "recordId": "market-cjc-1295-dac", "name": "CJC-1295 DAC", "aliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceCategory": "market", "evidenceCategoryLabel": "US research-market price board", "family": "Growth-signaling analogues", "sponsorCompanyOrBoard": "5 mg like-for-like comparison", "currentStatus": "2 of 3 rows in stock", "routeOrListingDetail": "Drug-affinity-complex growth hormone-releasing factor analogue research material", "questionAnswered": "What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access?", "interpretationBoundary": "Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.", "linkedEvidenceRecords": 4, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/products/cjc-1295-dac", "sourceLabel": "Read the FDA source", "sourcePublisher": "U.S. Food and Drug Administration", "sourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" }, { "recordId": "market-cjc-1295-no-dac", "name": "CJC-1295 no DAC", "aliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceCategory": "market", "evidenceCategoryLabel": "US research-market price board", "family": "Growth-signaling analogues", "sponsorCompanyOrBoard": "5 mg like-for-like comparison", "currentStatus": "2 of 3 rows in stock", "routeOrListingDetail": "Modified growth hormone-releasing factor analogue research material", "questionAnswered": "What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access?", "interpretationBoundary": "Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.", "linkedEvidenceRecords": 4, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/products/cjc-1295-no-dac", "sourceLabel": "Read the FDA source", "sourcePublisher": "U.S. Food and Drug Administration", "sourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" }, { "recordId": "market-dsip", "name": "DSIP", "aliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide" ], "evidenceCategory": "market", "evidenceCategoryLabel": "US research-market price board", "family": "Neuropeptides", "sponsorCompanyOrBoard": "5 mg like-for-like comparison", "currentStatus": "2 of 3 rows in stock", "routeOrListingDetail": "Synthetic delta sleep-inducing nonapeptide research material", "questionAnswered": "What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access?", "interpretationBoundary": "Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.", "linkedEvidenceRecords": 4, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/products/dsip", "sourceLabel": "Read the FDA source", "sourcePublisher": "U.S. Food and Drug Administration", "sourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" }, { "recordId": "pipeline-ecnoglutide", "name": "Ecnoglutide", "aliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceCategory": "pipeline", "evidenceCategoryLabel": "Investigational clinical program", "family": "Obesity and metabolic pipeline", "sponsorCompanyOrBoard": "Sciwind Biosciences; Pfizer commercialization partner in Mainland China", "currentStatus": "China approvals active; indication-expansion studies continue", "routeOrListingDetail": "cAMP-signalling-biased GLP-1 receptor agonist · Once-weekly subcutaneous injection", "questionAnswered": "Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program?", "interpretationBoundary": "Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.", "linkedEvidenceRecords": 8, "clinicalTrialRecords": 15, "recruitingClinicalTrials": 3, "postedTrialResults": 0, "clinicalTrialFinderPath": "/clinical-trials?program=ecnoglutide#trial-results", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Exact named-intervention match in the current 13-program ClinicalTrials.gov snapshot. Registry status, location, and posted results are separate fields and do not establish eligibility, access, approval, or benefit-risk.", "checkedDate": "2026-07-18", "profilePath": "/pipeline/ecnoglutide", "sourceLabel": "SLIMMER Phase 3 study - NCT05813795", "sourcePublisher": "ClinicalTrials.gov", "sourceUrl": "https://clinicaltrials.gov/study/NCT05813795" }, { "recordId": "medicine-egrifta-wr", "name": "EGRIFTA WR (Tesamorelin)", "aliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog" ], "evidenceCategory": "medicine", "evidenceCategoryLabel": "FDA-approved medicine", "family": "FDA-approved GHRF-analog medicine", "sponsorCompanyOrBoard": "Theratechnologies Inc.", "currentStatus": "BLA 022505 · FDA-approved prescription drug", "routeOrListingDetail": "Lyophilized powder kit · Subcutaneous", "questionAnswered": "Which exact product, application, label company, route, and regulatory record did FDA approve?", "interpretationBoundary": "Approval applies to the exact medicine and label record. It does not transfer to compounded products, research listings, or similarly named materials, and it does not determine individual suitability.", "linkedEvidenceRecords": 2, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/medicines/egrifta-wr", "sourceLabel": "Current EGRIFTA WR prescribing information", "sourcePublisher": "National Library of Medicine, DailyMed", "sourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75" }, { "recordId": "pipeline-eloralintide", "name": "Eloralintide", "aliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceCategory": "pipeline", "evidenceCategoryLabel": "Investigational clinical program", "family": "Obesity and metabolic pipeline", "sponsorCompanyOrBoard": "Eli Lilly and Company", "currentStatus": "Phase 3 ENLIGHTEN program recruiting", "routeOrListingDetail": "Selective amylin 1 receptor agonist · Once-weekly subcutaneous injection", "questionAnswered": "Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program?", "interpretationBoundary": "Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.", "linkedEvidenceRecords": 9, "clinicalTrialRecords": 19, "recruitingClinicalTrials": 11, "postedTrialResults": 1, "clinicalTrialFinderPath": "/clinical-trials?program=eloralintide#trial-results", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Exact named-intervention match in the current 13-program ClinicalTrials.gov snapshot. Registry status, location, and posted results are separate fields and do not establish eligibility, access, approval, or benefit-risk.", "checkedDate": "2026-07-22", "profilePath": "/pipeline/eloralintide", "sourceLabel": "Eloralintide Phase 2 study - NCT06230523", "sourcePublisher": "ClinicalTrials.gov", "sourceUrl": "https://clinicaltrials.gov/study/NCT06230523" }, { "recordId": "pipeline-enicepatide", "name": "Enicepatide", "aliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceCategory": "pipeline", "evidenceCategoryLabel": "Investigational clinical program", "family": "Obesity and metabolic pipeline", "sponsorCompanyOrBoard": "Roche / Carmot Therapeutics", "currentStatus": "Phase 3 ENITH program recruiting", "routeOrListingDetail": "Signal-biased GLP-1 + GIP receptor dual agonist · Once-weekly subcutaneous injection", "questionAnswered": "Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program?", "interpretationBoundary": "Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.", "linkedEvidenceRecords": 6, "clinicalTrialRecords": 8, "recruitingClinicalTrials": 4, "postedTrialResults": 0, "clinicalTrialFinderPath": "/clinical-trials?program=enicepatide#trial-results", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Exact named-intervention match in the current 13-program ClinicalTrials.gov snapshot. Registry status, location, and posted results are separate fields and do not establish eligibility, access, approval, or benefit-risk.", "checkedDate": "2026-07-18", "profilePath": "/pipeline/enicepatide", "sourceLabel": "CT388-103 Phase 2 study - NCT06525935", "sourcePublisher": "ClinicalTrials.gov", "sourceUrl": "https://clinicaltrials.gov/study/NCT06525935" }, { "recordId": "medicine-foundayo", "name": "FOUNDAYO (Orforglipron)", "aliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceCategory": "medicine", "evidenceCategoryLabel": "FDA-approved medicine", "family": "FDA-approved non-peptide GLP-1 comparator", "sponsorCompanyOrBoard": "Lilly USA, LLC", "currentStatus": "NDA 220934 · FDA-approved prescription drug", "routeOrListingDetail": "Film-coated tablets · Oral", "questionAnswered": "Which exact product, application, label company, route, and regulatory record did FDA approve?", "interpretationBoundary": "Approval applies to the exact medicine and label record. It does not transfer to compounded products, research listings, or similarly named materials, and it does not determine individual suitability.", "linkedEvidenceRecords": 6, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-20", "profilePath": "/medicines/foundayo", "sourceLabel": "Current FOUNDAYO prescribing information", "sourcePublisher": "National Library of Medicine, DailyMed", "sourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62" }, { "recordId": "market-ghk-cu", "name": "GHK-Cu", "aliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceCategory": "market", "evidenceCategoryLabel": "US research-market price board", "family": "Copper and short peptides", "sponsorCompanyOrBoard": "100 mg like-for-like comparison", "currentStatus": "3 of 5 rows in stock", "routeOrListingDetail": "Copper tripeptide research material", "questionAnswered": "What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access?", "interpretationBoundary": "Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.", "linkedEvidenceRecords": 6, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/products/ghk-cu", "sourceLabel": "Read the PubChem compound record", "sourcePublisher": "National Library of Medicine, PubChem", "sourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328" }, { "recordId": "market-igf-1-lr3", "name": "IGF-1 LR3", "aliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3" ], "evidenceCategory": "market", "evidenceCategoryLabel": "US research-market price board", "family": "Growth-signaling analogues", "sponsorCompanyOrBoard": "0.1 mg like-for-like comparison", "currentStatus": "1 of 3 rows in stock", "routeOrListingDetail": "Long-arginine-3 insulin-like growth factor analogue research reagent", "questionAnswered": "What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access?", "interpretationBoundary": "Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.", "linkedEvidenceRecords": 4, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/products/igf-1-lr3", "sourceLabel": "Read the PubChem substance record", "sourcePublisher": "National Library of Medicine, PubChem", "sourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731" }, { "recordId": "market-ipamorelin", "name": "Ipamorelin", "aliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceCategory": "market", "evidenceCategoryLabel": "US research-market price board", "family": "Growth-signaling analogues", "sponsorCompanyOrBoard": "10 mg like-for-like comparison", "currentStatus": "3 of 3 rows in stock", "routeOrListingDetail": "Synthetic growth hormone secretagogue research material", "questionAnswered": "What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access?", "interpretationBoundary": "Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.", "linkedEvidenceRecords": 4, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/products/ipamorelin", "sourceLabel": "Read the FDA source", "sourcePublisher": "U.S. Food and Drug Administration", "sourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" }, { "recordId": "market-kisspeptin-10", "name": "Kisspeptin-10", "aliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide" ], "evidenceCategory": "market", "evidenceCategoryLabel": "US research-market price board", "family": "Reproductive-signaling peptides", "sponsorCompanyOrBoard": "10 mg like-for-like comparison", "currentStatus": "2 of 3 rows in stock", "routeOrListingDetail": "Synthetic kisspeptin decapeptide research material", "questionAnswered": "What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access?", "interpretationBoundary": "Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.", "linkedEvidenceRecords": 4, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/products/kisspeptin-10", "sourceLabel": "Read the PubChem compound record", "sourcePublisher": "National Library of Medicine, PubChem", "sourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297" }, { "recordId": "pipeline-maritide", "name": "MariTide", "aliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceCategory": "pipeline", "evidenceCategoryLabel": "Investigational clinical program", "family": "Obesity and metabolic pipeline", "sponsorCompanyOrBoard": "Amgen", "currentStatus": "Phase 3 program active", "routeOrListingDetail": "GLP-1 receptor agonist + GIP receptor antagonist · Subcutaneous injection", "questionAnswered": "Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program?", "interpretationBoundary": "Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.", "linkedEvidenceRecords": 4, "clinicalTrialRecords": 27, "recruitingClinicalTrials": 6, "postedTrialResults": 2, "clinicalTrialFinderPath": "/clinical-trials?program=maritide#trial-results", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Exact named-intervention match in the current 13-program ClinicalTrials.gov snapshot. Registry status, location, and posted results are separate fields and do not establish eligibility, access, approval, or benefit-risk.", "checkedDate": "2026-07-20", "profilePath": "/pipeline/maritide", "sourceLabel": "Phase 2 dose-ranging study - NCT05669599", "sourcePublisher": "ClinicalTrials.gov", "sourceUrl": "https://clinicaltrials.gov/study/NCT05669599" }, { "recordId": "pipeline-mazdutide", "name": "Mazdutide", "aliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceCategory": "pipeline", "evidenceCategoryLabel": "Investigational clinical program", "family": "Obesity and metabolic pipeline", "sponsorCompanyOrBoard": "Innovent Biologics; licensed from Eli Lilly for China", "currentStatus": "China approvals active; Phase 3 and indication-expansion studies continue", "routeOrListingDetail": "GLP-1 and glucagon receptor dual agonist · Once-weekly subcutaneous injection", "questionAnswered": "Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program?", "interpretationBoundary": "Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.", "linkedEvidenceRecords": 10, "clinicalTrialRecords": 37, "recruitingClinicalTrials": 10, "postedTrialResults": 1, "clinicalTrialFinderPath": "/clinical-trials?program=mazdutide#trial-results", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Exact named-intervention match in the current 13-program ClinicalTrials.gov snapshot. Registry status, location, and posted results are separate fields and do not establish eligibility, access, approval, or benefit-risk.", "checkedDate": "2026-07-22", "profilePath": "/pipeline/mazdutide", "sourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "sourcePublisher": "ClinicalTrials.gov", "sourceUrl": "https://clinicaltrials.gov/study/NCT05607680" }, { "recordId": "market-melanotan-i", "name": "Melanotan I", "aliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceCategory": "market", "evidenceCategoryLabel": "US research-market price board", "family": "Melanocortin analogues", "sponsorCompanyOrBoard": "10 mg like-for-like comparison", "currentStatus": "2 of 3 rows in stock", "routeOrListingDetail": "Synthetic linear alpha-melanocyte-stimulating hormone analogue research material", "questionAnswered": "What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access?", "interpretationBoundary": "Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.", "linkedEvidenceRecords": 4, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/products/melanotan-i", "sourceLabel": "Read the current SCENESSE label", "sourcePublisher": "National Library of Medicine, DailyMed", "sourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48" }, { "recordId": "market-melanotan-ii", "name": "Melanotan II", "aliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceCategory": "market", "evidenceCategoryLabel": "US research-market price board", "family": "Melanocortin analogues", "sponsorCompanyOrBoard": "10 mg like-for-like comparison", "currentStatus": "1 of 3 rows in stock", "routeOrListingDetail": "Synthetic cyclic melanocortin analogue research material", "questionAnswered": "What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access?", "interpretationBoundary": "Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.", "linkedEvidenceRecords": 4, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/products/melanotan-ii", "sourceLabel": "Read the FDA source", "sourcePublisher": "U.S. Food and Drug Administration", "sourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" }, { "recordId": "market-mots-c", "name": "MOTS-c", "aliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceCategory": "market", "evidenceCategoryLabel": "US research-market price board", "family": "Mitochondrial and metabolic", "sponsorCompanyOrBoard": "10 mg like-for-like comparison", "currentStatus": "5 of 7 rows in stock", "routeOrListingDetail": "Mitochondria-derived peptide research material", "questionAnswered": "What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access?", "interpretationBoundary": "Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.", "linkedEvidenceRecords": 8, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/products/mots-c", "sourceLabel": "Read the FDA source", "sourcePublisher": "U.S. Food and Drug Administration", "sourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" }, { "recordId": "market-nad-plus", "name": "NAD+", "aliases": [ "Nicotinamide adenine dinucleotide", "NAD plus" ], "evidenceCategory": "market", "evidenceCategoryLabel": "US research-market price board", "family": "Mitochondrial and metabolic", "sponsorCompanyOrBoard": "1000 mg like-for-like comparison", "currentStatus": "3 of 4 rows in stock", "routeOrListingDetail": "Dinucleotide coenzyme research material (not a peptide)", "questionAnswered": "What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access?", "interpretationBoundary": "Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.", "linkedEvidenceRecords": 5, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/products/nad-plus", "sourceLabel": "Read the PubChem compound record", "sourcePublisher": "National Library of Medicine, PubChem", "sourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN" }, { "recordId": "pipeline-pemvidutide", "name": "Pemvidutide", "aliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceCategory": "pipeline", "evidenceCategoryLabel": "Investigational clinical program", "family": "Obesity and metabolic pipeline", "sponsorCompanyOrBoard": "Altimmune", "currentStatus": "Phase 2 programs active; MASH Phase 3 planned", "routeOrListingDetail": "Balanced 1:1 GLP-1 and glucagon receptor dual agonist · Once-weekly subcutaneous injection", "questionAnswered": "Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program?", "interpretationBoundary": "Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.", "linkedEvidenceRecords": 9, "clinicalTrialRecords": 9, "recruitingClinicalTrials": 1, "postedTrialResults": 0, "clinicalTrialFinderPath": "/clinical-trials?program=pemvidutide#trial-results", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Exact named-intervention match in the current 13-program ClinicalTrials.gov snapshot. Registry status, location, and posted results are separate fields and do not establish eligibility, access, approval, or benefit-risk.", "checkedDate": "2026-07-18", "profilePath": "/pipeline/pemvidutide", "sourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "sourcePublisher": "ClinicalTrials.gov", "sourceUrl": "https://clinicaltrials.gov/study/NCT05989711" }, { "recordId": "pipeline-petrelintide", "name": "Petrelintide", "aliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceCategory": "pipeline", "evidenceCategoryLabel": "Investigational clinical program", "family": "Obesity and metabolic pipeline", "sponsorCompanyOrBoard": "Zealand Pharma + Roche", "currentStatus": "Phase 3 planned; Phase 2 program active", "routeOrListingDetail": "Long-acting amylin analogue · Once-weekly subcutaneous injection", "questionAnswered": "Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program?", "interpretationBoundary": "Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.", "linkedEvidenceRecords": 5, "clinicalTrialRecords": 9, "recruitingClinicalTrials": 2, "postedTrialResults": 0, "clinicalTrialFinderPath": "/clinical-trials?program=petrelintide#trial-results", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Exact named-intervention match in the current 13-program ClinicalTrials.gov snapshot. Registry status, location, and posted results are separate fields and do not establish eligibility, access, approval, or benefit-risk.", "checkedDate": "2026-07-17", "profilePath": "/pipeline/petrelintide", "sourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "sourcePublisher": "ClinicalTrials.gov", "sourceUrl": "https://clinicaltrials.gov/study/NCT06662539" }, { "recordId": "market-pt-141", "name": "PT-141 (Bremelanotide)", "aliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceCategory": "market", "evidenceCategoryLabel": "US research-market price board", "family": "Melanocortin analogues", "sponsorCompanyOrBoard": "10 mg like-for-like comparison", "currentStatus": "2 of 3 rows in stock", "routeOrListingDetail": "Synthetic melanocortin-receptor agonist research material", "questionAnswered": "What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access?", "interpretationBoundary": "Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.", "linkedEvidenceRecords": 4, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/products/pt-141", "sourceLabel": "Read the current DailyMed drug label", "sourcePublisher": "National Library of Medicine, DailyMed", "sourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf" }, { "recordId": "pipeline-retatrutide", "name": "Retatrutide", "aliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceCategory": "pipeline", "evidenceCategoryLabel": "Investigational clinical program", "family": "Obesity and metabolic pipeline", "sponsorCompanyOrBoard": "Eli Lilly and Company", "currentStatus": "Phase 3 program reporting results", "routeOrListingDetail": "GIP + GLP-1 + glucagon receptor agonist · Once-weekly subcutaneous injection", "questionAnswered": "Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program?", "interpretationBoundary": "Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.", "linkedEvidenceRecords": 4, "clinicalTrialRecords": 34, "recruitingClinicalTrials": 2, "postedTrialResults": 2, "clinicalTrialFinderPath": "/clinical-trials?program=retatrutide#trial-results", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Exact named-intervention match in the current 13-program ClinicalTrials.gov snapshot. Registry status, location, and posted results are separate fields and do not establish eligibility, access, approval, or benefit-risk.", "checkedDate": "2026-07-20", "profilePath": "/pipeline/retatrutide", "sourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "sourcePublisher": "ClinicalTrials.gov", "sourceUrl": "https://clinicaltrials.gov/study/NCT05929066" }, { "recordId": "medicine-saxenda", "name": "SAXENDA (Liraglutide)", "aliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist" ], "evidenceCategory": "medicine", "evidenceCategoryLabel": "FDA-approved medicine", "family": "FDA-approved incretin medicine", "sponsorCompanyOrBoard": "Novo Nordisk Inc.", "currentStatus": "NDA 206321 · FDA-approved prescription drug", "routeOrListingDetail": "Injection · Subcutaneous", "questionAnswered": "Which exact product, application, label company, route, and regulatory record did FDA approve?", "interpretationBoundary": "Approval applies to the exact medicine and label record. It does not transfer to compounded products, research listings, or similarly named materials, and it does not determine individual suitability.", "linkedEvidenceRecords": 2, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/medicines/saxenda", "sourceLabel": "Current SAXENDA prescribing information", "sourcePublisher": "National Library of Medicine, DailyMed", "sourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143" }, { "recordId": "medicine-scenesse", "name": "SCENESSE (Afamelanotide)", "aliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog" ], "evidenceCategory": "medicine", "evidenceCategoryLabel": "FDA-approved medicine", "family": "FDA-approved melanocortin medicine", "sponsorCompanyOrBoard": "CLINUVEL INC.", "currentStatus": "NDA 210797 · FDA-approved prescription drug", "routeOrListingDetail": "Implant · Subcutaneous", "questionAnswered": "Which exact product, application, label company, route, and regulatory record did FDA approve?", "interpretationBoundary": "Approval applies to the exact medicine and label record. It does not transfer to compounded products, research listings, or similarly named materials, and it does not determine individual suitability.", "linkedEvidenceRecords": 2, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/medicines/scenesse", "sourceLabel": "Current SCENESSE prescribing information", "sourcePublisher": "National Library of Medicine, DailyMed", "sourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48" }, { "recordId": "market-selank", "name": "Selank", "aliases": [ "TP-7", "selank acetate" ], "evidenceCategory": "market", "evidenceCategoryLabel": "US research-market price board", "family": "Neuropeptides", "sponsorCompanyOrBoard": "10 mg like-for-like comparison", "currentStatus": "2 of 3 rows in stock", "routeOrListingDetail": "Synthetic heptapeptide research material", "questionAnswered": "What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access?", "interpretationBoundary": "Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.", "linkedEvidenceRecords": 4, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/products/selank", "sourceLabel": "Read the FDA source", "sourcePublisher": "U.S. Food and Drug Administration", "sourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" }, { "recordId": "market-semax", "name": "Semax", "aliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceCategory": "market", "evidenceCategoryLabel": "US research-market price board", "family": "Neuropeptides", "sponsorCompanyOrBoard": "10 mg like-for-like comparison", "currentStatus": "3 of 3 rows in stock", "routeOrListingDetail": "Synthetic ACTH-fragment analogue research material", "questionAnswered": "What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access?", "interpretationBoundary": "Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.", "linkedEvidenceRecords": 4, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/products/semax", "sourceLabel": "Read the FDA source", "sourcePublisher": "U.S. Food and Drug Administration", "sourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" }, { "recordId": "market-sermorelin", "name": "Sermorelin", "aliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceCategory": "market", "evidenceCategoryLabel": "US research-market price board", "family": "Growth-signaling analogues", "sponsorCompanyOrBoard": "5 mg like-for-like comparison", "currentStatus": "2 of 3 rows in stock", "routeOrListingDetail": "Synthetic growth hormone-releasing hormone fragment research material", "questionAnswered": "What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access?", "interpretationBoundary": "Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.", "linkedEvidenceRecords": 4, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/products/sermorelin", "sourceLabel": "Read the FDA orphan-drug record", "sourcePublisher": "U.S. Food and Drug Administration", "sourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687" }, { "recordId": "pipeline-survodutide", "name": "Survodutide", "aliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceCategory": "pipeline", "evidenceCategoryLabel": "Investigational clinical program", "family": "Obesity and metabolic pipeline", "sponsorCompanyOrBoard": "Boehringer Ingelheim + Zealand Pharma", "currentStatus": "Phase 3 program active and reporting", "routeOrListingDetail": "Glucagon + GLP-1 receptor dual agonist · Once-weekly subcutaneous injection", "questionAnswered": "Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program?", "interpretationBoundary": "Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.", "linkedEvidenceRecords": 7, "clinicalTrialRecords": 31, "recruitingClinicalTrials": 3, "postedTrialResults": 3, "clinicalTrialFinderPath": "/clinical-trials?program=survodutide#trial-results", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Exact named-intervention match in the current 13-program ClinicalTrials.gov snapshot. Registry status, location, and posted results are separate fields and do not establish eligibility, access, approval, or benefit-risk.", "checkedDate": "2026-07-20", "profilePath": "/pipeline/survodutide", "sourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "sourcePublisher": "ClinicalTrials.gov", "sourceUrl": "https://clinicaltrials.gov/study/NCT06066515" }, { "recordId": "market-tb-500", "name": "TB-500", "aliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceCategory": "market", "evidenceCategoryLabel": "US research-market price board", "family": "Tissue and thymic peptides", "sponsorCompanyOrBoard": "10 mg like-for-like comparison", "currentStatus": "5 of 7 rows in stock", "routeOrListingDetail": "Thymosin beta-4 research material", "questionAnswered": "What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access?", "interpretationBoundary": "Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.", "linkedEvidenceRecords": 8, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/products/tb-500", "sourceLabel": "Read the FDA source", "sourcePublisher": "U.S. Food and Drug Administration", "sourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" }, { "recordId": "market-tesamorelin", "name": "Tesamorelin", "aliases": [ "Egrifta", "TH9507" ], "evidenceCategory": "market", "evidenceCategoryLabel": "US research-market price board", "family": "Growth-signaling analogues", "sponsorCompanyOrBoard": "10 mg like-for-like comparison", "currentStatus": "4 of 5 rows in stock", "routeOrListingDetail": "Synthetic growth hormone-releasing factor analog research material", "questionAnswered": "What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access?", "interpretationBoundary": "Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.", "linkedEvidenceRecords": 6, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/products/tesamorelin", "sourceLabel": "Check the FDA Purple Book product record", "sourcePublisher": "U.S. Food and Drug Administration", "sourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails" }, { "recordId": "market-thymosin-alpha-1", "name": "Thymosin Alpha-1", "aliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1" ], "evidenceCategory": "market", "evidenceCategoryLabel": "US research-market price board", "family": "Tissue and thymic peptides", "sponsorCompanyOrBoard": "5 mg like-for-like comparison", "currentStatus": "2 of 3 rows in stock", "routeOrListingDetail": "Synthetic 28-amino-acid thymic peptide research material", "questionAnswered": "What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access?", "interpretationBoundary": "Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.", "linkedEvidenceRecords": 4, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/products/thymosin-alpha-1", "sourceLabel": "Read the FDA source", "sourcePublisher": "U.S. Food and Drug Administration", "sourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" }, { "recordId": "pipeline-vk2735", "name": "VK2735", "aliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceCategory": "pipeline", "evidenceCategoryLabel": "Investigational clinical program", "family": "Obesity and metabolic pipeline", "sponsorCompanyOrBoard": "Viking Therapeutics", "currentStatus": "Subcutaneous Phase 3 active; oral Phase 3 planned", "routeOrListingDetail": "GIP and GLP-1 receptor dual agonist · Once-weekly subcutaneous injection and once-daily oral tablet", "questionAnswered": "Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program?", "interpretationBoundary": "Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.", "linkedEvidenceRecords": 8, "clinicalTrialRecords": 5, "recruitingClinicalTrials": 0, "postedTrialResults": 0, "clinicalTrialFinderPath": "/clinical-trials?program=vk2735#trial-results", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Exact named-intervention match in the current 13-program ClinicalTrials.gov snapshot. Registry status, location, and posted results are separate fields and do not establish eligibility, access, approval, or benefit-risk.", "checkedDate": "2026-07-18", "profilePath": "/pipeline/vk2735", "sourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "sourcePublisher": "ClinicalTrials.gov", "sourceUrl": "https://clinicaltrials.gov/study/NCT06068946" }, { "recordId": "medicine-vyleesi", "name": "VYLEESI (Bremelanotide)", "aliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist" ], "evidenceCategory": "medicine", "evidenceCategoryLabel": "FDA-approved medicine", "family": "FDA-approved melanocortin medicine", "sponsorCompanyOrBoard": "Cosette Pharmaceuticals, Inc.", "currentStatus": "NDA 210557 · FDA-approved prescription drug", "routeOrListingDetail": "Injection · Subcutaneous", "questionAnswered": "Which exact product, application, label company, route, and regulatory record did FDA approve?", "interpretationBoundary": "Approval applies to the exact medicine and label record. It does not transfer to compounded products, research listings, or similarly named materials, and it does not determine individual suitability.", "linkedEvidenceRecords": 2, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/medicines/vyleesi", "sourceLabel": "Current VYLEESI prescribing information", "sourcePublisher": "National Library of Medicine, DailyMed", "sourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf" }, { "recordId": "medicine-wegovy", "name": "WEGOVY (Semaglutide)", "aliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽" ], "evidenceCategory": "medicine", "evidenceCategoryLabel": "FDA-approved medicine", "family": "FDA-approved incretin medicine", "sponsorCompanyOrBoard": "Novo Nordisk Inc.", "currentStatus": "NDA 215256 · FDA-approved prescription drug", "routeOrListingDetail": "Injection and tablets · Subcutaneous and oral", "questionAnswered": "Which exact product, application, label company, route, and regulatory record did FDA approve?", "interpretationBoundary": "Approval applies to the exact medicine and label record. It does not transfer to compounded products, research listings, or similarly named materials, and it does not determine individual suitability.", "linkedEvidenceRecords": 7, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-18", "profilePath": "/medicines/wegovy", "sourceLabel": "Current WEGOVY prescribing information", "sourcePublisher": "National Library of Medicine, DailyMed", "sourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b" }, { "recordId": "pipeline-amycretin", "name": "Zenagamtide", "aliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceCategory": "pipeline", "evidenceCategoryLabel": "Investigational clinical program", "family": "Obesity and metabolic pipeline", "sponsorCompanyOrBoard": "Novo Nordisk", "currentStatus": "Phase 3 development underway", "routeOrListingDetail": "GLP-1 + amylin receptor agonist · Once-daily oral or once-weekly subcutaneous", "questionAnswered": "Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program?", "interpretationBoundary": "Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.", "linkedEvidenceRecords": 5, "clinicalTrialRecords": 24, "recruitingClinicalTrials": 10, "postedTrialResults": 0, "clinicalTrialFinderPath": "/clinical-trials?program=amycretin#trial-results", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Exact named-intervention match in the current 13-program ClinicalTrials.gov snapshot. Registry status, location, and posted results are separate fields and do not establish eligibility, access, approval, or benefit-risk.", "checkedDate": "2026-07-20", "profilePath": "/pipeline/amycretin", "sourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "sourcePublisher": "ClinicalTrials.gov", "sourceUrl": "https://clinicaltrials.gov/study/NCT07668414" }, { "recordId": "medicine-zepbound", "name": "ZEPBOUND (Tirzepatide)", "aliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceCategory": "medicine", "evidenceCategoryLabel": "FDA-approved medicine", "family": "FDA-approved incretin medicine", "sponsorCompanyOrBoard": "Lilly USA, LLC", "currentStatus": "NDA 217806 · FDA-approved prescription drug", "routeOrListingDetail": "Injection · Subcutaneous", "questionAnswered": "Which exact product, application, label company, route, and regulatory record did FDA approve?", "interpretationBoundary": "Approval applies to the exact medicine and label record. It does not transfer to compounded products, research listings, or similarly named materials, and it does not determine individual suitability.", "linkedEvidenceRecords": 2, "clinicalTrialRecords": null, "recruitingClinicalTrials": null, "postedTrialResults": null, "clinicalTrialFinderPath": "/clinical-trials", "clinicalTrialSnapshotVersion": "2026-07-24", "clinicalTrialCoverageScope": "Not linked by the current 13-program investigational snapshot. A blank count is a scope boundary, not evidence that no clinical trial or trial history exists.", "checkedDate": "2026-07-17", "profilePath": "/medicines/zepbound", "sourceLabel": "Current ZEPBOUND prescribing information", "sourcePublisher": "National Library of Medicine, DailyMed", "sourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38" } ] }